Back to search

Aristotle University Of Thessaloniki (AUTH)

Επίδρασις των αντισωμάτων έναντι της γαγγλιοσίδης GMI στα εκφυλιστικά νοσήματα του κεντρικού νευρικού συστήματος και η σημασία της στην θεραπευτική αντιμετώπιση των νόσων αυτών

Abstract

dc:description

The aim of the present investigation was to determine the levels of anti-GM1 IgM in the sera of patients suffering from several types of dementia, including A.D, multiple sclerosis (MS), Parkinson’s disease (PD), motor neuron disease (MND) as well as with olivo-ponto-cerebellar atrophy. The levels of anti-GM1 IgM have also been correlated with other anti-ganglioside antibodies such as anti-GD1b IgM and anti-GQb IgM, as well as with clinical parameters, in order to find out a possible role in the pathogenesis of the examined degenerated disorders and their role in the therapeutic approach. For the determination of the concentrations of the three anti-ganglioside antibodies, the Elisa technique was used. 103 demented patients have been examined. They suffered from several types of dementia including Alzheimer’s disease and had a mean age of 71.3±8.4. 60 healthy individuals with a mean age of 71.3±7.4 have also been examined for the presence of anti-ganglioside antibodies in their sera. 36% (Ν=37) of the patients suffered from vascular dementia, 23% (Ν=24) from the frontotemporal type, 17% (Ν=18) from A.D and in a lesser extent from pseudodementia (dementia due to depression) and Lewy Body dementia (LBDD). 66% (Ν=68) of the examined patients revealed pathological levels of antiGM1 IgM (37.7±8.9 EU/ml), 35% (Ν=36) anti-GD1b IgM (30.6±3.7 EU/ml) and only 9% (Ν=9) had increased concentrations of anti-GQ1b IgM. The healthy individuals demonstrated in their sera no pathological levels of either of the three antibodies (p=0.0005). The concentrations of the three anti-ganglioside antibodies have then been correlated with the age of the patients, the grade of cognitive impairment and the type of the disease. According to the results, patients with ages of 66-75 and 76-86 years revealed the highest anti-GM1 IgM concentrations (28.0±11.2 EU/ml and 37.0±9.1 EU/ml) (p=0.0005). There was no significant comparison with anti-GD1b and anti-GQ1b IgM (p>0.05) 305 Correlating the levels of the investigated antibodies with the grade of cognitive impairment, the present research revealed that patients with severe cognitive impairment (MMSE 1-18/30) demonstrated the most increased levels of anti-GM1 IgM (37.9±8.9 EU/ml) (p=0.0005). There was no correlation with anti-GD1b IgM or anti-GQ1b IgM. According to this investigation there was a border-correlation (but not very significant) between the types of dementia and the anti-GM1 IgM (p=0.048). 37% of the patients with concentrations between 26-61 EU/ml suffered from vascular dementia, 35% with an intermediate border-concentration suffered from vascular and 35% from frontotemporal type, while 36% with mixed dementia or A.D revealed normal levels. There was no significant correlation with anti-GQ1b IgM, whereas an important correlation was found with the anti-GD1b IgM levels. Patients with anti-GD1b levels of 27.4±8.4 EU/ml suffered from A.D, patients with an intermediate border concentration of anti-GD1b suffered from mixed dementia, while patients with vascular dementia revealed normal concentrations of anti-GD1b IgM (p0.05), whereas the results demonstrated that patients with severe disability (EDSS 4-6) had a long duration of the MS (8.9-14 years). 306 No significant correlation was also found between levels of antibodies and the therapeutic approach. In Parkinson’s disease (PD) 44 patients have been examined, with an age of 67.0±11.9 years and 44 healthy individuals of a common age (63.5±11.3 years). The patients demonstrated mean scores in UPDRS III: 17.0±14.9, in UPDRS I: 2.7±2.5 and a mild cognitive impairment (MMSE: 24.2±7.5/30). None of the healthy controls revealed pathological levels of the three anti-ganglioside antibodies compared with the patients (p=0.0005), who demonstrated at 68% (Ν=30) pathological levels of anti-GM1 IgM (32.4±5.9 EU/ml), 34% (N=15) had also increased concentrations of anti-GD1b IgM (27.3±1.6 EU/ml), whereas none of them revealed pathological levels of anti-GQ1b IgM in their sera. Comparisons with the age of the patients, with the type of the therapy as well as with the grade of disability revealed no significant correlations (p>0.05). Comparisons of the anti-ganglioside antibodies with the grade of cognitive impairment revealed that patients with mild (UPDRS I:4-6, MMSE: 16-25/30) or severe cognitive impairment (UPDRS I:7-9, MMSE: 0-15/30) demonstrated the most increased concentrations of anti-GM1 IgM (25-33 EU/ml) (p0.05). The levels of the investigated anti-ganglioside antibodies have also been compared with the levels in the sera of patients suffered from other degenerative disorders of the central nervous system. These patients revealed higher levels of anti-GM1 IgM (34.7±10.2 EU/ml) correlated with the demented patients, as wells with the MS- or PD-patients. Due to the small number of patients with MND or olivo-ponto-cerebellar atrophy, more conclusions could not be made. However the present comparison revealed that the highest concentrations of anti-GD1b IgM 307 demonstrated patients suffered from MS (27.5±9.7 EU/ml), whereas antiGQ1b IgM have been determined only in normal levels. Αccording to the present results, anti-ganglioside antibodies are indicative for the neurodegeneration. The investigation of the gangliosides and the antibodies against these molecules is the key for understanding the exact role of glycosphingolipids in the pathogenesis of neurodegenerative diseases of the CNS.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Hatzifilippou, Eleni
  • Χατζηφιλίππου, Ελένη

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/33167

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Hatzifilippou, Eleni; Χατζηφιλίππου, Ελένη. Επίδρασις των αντισωμάτων έναντι της γαγγλιοσίδης GMI στα εκφυλιστικά νοσήματα του κεντρικού νευρικού συστήματος και η σημασία της στην θεραπευτική αντιμετώπιση των νόσων αυτών. Aristotle University Of Thessaloniki (AUTH), 2011. http://hdl.handle.net/10442/hedi/33167